New obesity drugs are posting surgical-scale weight-loss numbers. Is the gap closing, or are we mistaking early results for the final answer?

Qure may seek approval in the UK first while in talks with the FDA about its request for a larger, sham-controlled trial of ...

Prior authorization remains a major barrier to biologic access in AD. Dr Chuck Vega covers denial rates, appeal outcomes, and the clinical data that make the fight worthwhile.